Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics

NACompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 23, 2018

Primary Completion Date

December 18, 2018

Study Completion Date

December 31, 2018

Conditions
Type1diabetesType1 Diabetes Mellitus
Interventions
DIETARY_SUPPLEMENT

VSL#3

VSL#3 is a commercially available probiotic supplement manufactured and distributed by Alfasigma USA, Inc of Covington, Louisiana, USA. As with other probiotics, VSL#3 is considered a supplement and is not FDA-approved or regulated. VSL#3 contains eight probiotic strains: bifidobacteria (B. longum, B. infantis, and B. breve), lactobacilli (L. acidophilus, L. casei, L. bulgaricus, and L. plantarum) and Strepococcus thermophiles.

Trial Locations (1)

53226

Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT03423589 - Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics | Biotech Hunter | Biotech Hunter